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(42.7 − (Na + K − Cl)]). We could also identify metabolic 
acidosis with an increased anion gap using SIG > 7.0 
(SIG = 0.9463 × corrected anion gap—8.1956).
Conclusions Patients with nephrotic syndrome had pri-
mary respiratory alkalosis, decreased  ATOT due to hypoal-
buminemia (power to metabolic alkalosis), and decreased 
levels of SIDa (power to metabolic acidosis). We could 
detect metabolic acidosis with an increased anion gap by 
calculating SIG. The Stewart model in combination with 
the Boston model facilitates the analysis of complex acid–
base disturbances in nephrotic syndrome.
Keywords Acid–base disturbance · Metabolic acidosis · 
Nephrotic syndrome · Renin–angiotensin–aldosterone 
system · Respiratory alkalosis
Introduction
Several methods for analyzing acid–base disturbances 
have been proposed. One method is the traditional Boston 
model based on the  CO2/HCO3 method [1, 2]. Another is 
the Copenhagen-Danish model based on base excess (BE) 
[3, 4]. A third method is the Stewart model based on the 
physicochemical method [5–7]. The Boston model makes 
it easy for beginners to understand and analyze acid–base 
disturbances. However, without the use of compensatory 
formulas, this model is limited in the setting of complex 
conditions such as respiratory abnormalities and two 
or more concurrent metabolic abnormalities. The BE 
model is useful only in metabolic acidosis. In contrast, 
the Stewart model is theoretically superior to the other 
models mentioned above in complex situations because 
it is based on physicochemical data. However, it is very 
difficult for physicians to understand the underlying 
Abstract 
Background The Stewart model for analyzing acid–base 
disturbances emphasizes serum albumin levels, which are 
ignored in the traditional Boston model. We compared data 
derived using the Stewart model to those using the Boston 
model in patients with nephrotic syndrome.
Methods Twenty-nine patients with nephrotic syndrome 
and six patients without urinary protein or acid–base distur-
bances provided blood and urine samples for analysis that 
included routine biochemical and arterial blood gas tests, 
plasma renin activity, and aldosterone. The total concentra-
tion of non-volatile weak acids  (ATOT), apparent strong ion 
difference (SIDa), effective strong ion difference (SIDe), 
and strong ion gap (SIG) were calculated according to the 
formulas of Agrafiotis in the Stewart model.
Results According to the Boston model, 25 of 29 patients 
(90%) had alkalemia. Eighteen patients had respiratory 
alkalosis, 11 had metabolic alkalosis, and 4 had both con-
ditions. Only three patients had hyperreninemic hyperal-
dosteronism. The Stewart model demonstrated respiratory 
alkalosis based on decreased  PaCO2, metabolic alkalosis 
based on decreased  ATOT, and metabolic acidosis based 
on decreased SIDa. We could diagnose metabolic alkalo-
sis or acidosis with a normal anion gap after comparing 
delta  ATOT [(14.09 − measured  ATOT) or (11.77 − 2.64 × Alb 
(g/dL))] and delta SIDa [(42.7 − measured SIDa) or 
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concepts and make calculations using the relevant for-
mulas in clinical practice. The Stewart model emphasizes 
the importance of albumin (Alb), which carries a nega-
tive charge in serum and influences acid–base balance; 
Alb is not taken into account by the traditional Boston 
model. There have been no reports about acid–base dis-
turbances in nephrotic syndrome. In this study, we com-
pared data derived using the Stewart model to data from 
the traditional Boston model in the context of acid–base 
disturbances in patients with nephrotic syndrome.
Materials and methods
This study was approved by the Ethics Committee of Aichi 
Medical University (14-164).
Patient characteristics (Table 1)
We enrolled 29 patients with nephrotic syndrome and 6 
patients without urinary protein or acid–base disturbances 
as a control group. All patients were Japanese. They were 
admitted to Aichi Medical University Hospital between 
August 2014 and August 2015. The diagnosis of nephrotic 
Table 1  Characteristics and laboratory data of the study patients
MCNS minimal change nephrotic syndrome, endo-GN endocapillary proliferative glomerulonephritis, MN membranous nephropathy, FSGS 
focal segmental glomerulosclerosis, RA rheumatoid arthritis, DM diabetes mellitus, AL amyloid light chain, crescentic GN crescentic glomerulo-
nephritis, MPO-ANCA myeloperoxidase anti-neutrophil cytoplasmic antibody, U-protein urinary protein
Patient Age Gender Diagnosis U-protein TP Albumin BUN Cr eGFR IgG IgA IgM
(years) Renal biopsy Association g/day g/dL g/dL mg/dL mg/dL ml/min mg/dL mg/dL mg/dL
1 47 F Not done SLE 2.1 4.5 1.3 9.4 0.41 126 447 597 75
2 37 F MCNS 4.1 5.5 1.9 12.6 0.48 114 1677 264 125
3 55 M Not done Rectal cancer 5.2 5.2 2.1 11.6 0.58 111 1020 190 86
4 61 F endo-GN 9.6 5.0 1.8 12.4 0.59 78 818 336 115
5 32 F endo-GN 7.6 4.6 1.9 13.5 0.71 77 715 346 103
6 70 M MN 7.0 5.7 2.9 12.0 0.77 76 712 264 92
7 71 F MCNS 10.2 5.2 2.4 17.2 0.65 68 633 270 85
8 61 M MCNS 14.3 4.8 1.0 21.9 0.92 65 1011 687 111
9 76 F MCNS 10.7 3.9 0.9 34.8 0.73 58 746 154 36
10 65 M MCNS 3.7 4.8 1.4 11.6 1.01 58 542 546 144
11 81 F FSGS 7.0 5.5 2.8 25.5 0.75 56 541 165 45
12 78 F MCNS 4.8 4.4 1.8 11.1 0.81 52 366 218 87
13 75 M MCNS 10.7 3.6 1.1 33.5 1.10 51 422 244 33
14 89 F Not done 4.2 4.7 2.4 16.4 0.81 50 687 203 58
15 70 M MN 8.0 5.6 2.9 18.9 1.20 47 633 241 43
16 60 M Not done Thrombocytosis 11.0 4.5 1.9 18.7 1.46 40 866 224 40
17 60 M FSGS 18.2 3.5 0.9 37.2 1.72 33 467 412 114
18 81 M MN 5.7 4.2 1.8 25.4 1.61 33 604 224 74
19 87 F Not done MN suspected 6.5 4.6 1.8 24.2 1.20 33 734 529 21
20 71 F Not done MCNS suspected 12.3 4.4 1.4 78.0 1.38 30 362 314 123
21 86 M Not done MCNS suspected 3.9 4.1 0.8 27.9 1.76 29 1590 488 39
22 71 M Not done RA, bucillamine 7.5 5.1 2.1 45.8 1.97 27 883 60 104
23 54 M Not done DM 12.0 3.9 1.5 16.8 2.56 22 311 156 38
24 76 F Not done 17.3 5.5 1.0 20.5 2.02 19 2755 414 42
25 76 M Not done AL amyloidosis 4.6 4.1 1.8 46.0 3.57 14 647 48 19
26 77 F Crescentic GN 3.6 5.4 1.8 45.7 3.77 10 1290 285 42
27 82 M Not done DM 7.8 5.4 2.4 69.8 5.12 9 1022 192 58
28 74 F Crescentic GN 4.8 5.5 2.0 70.9 4.13 9 1146 362 52
29 70 F Not done MPO-ANCA 3.9 5.3 1.9 69.3 5.64 6 2285 636 108
Median 71 7.0 4.8 1.8 21.9 1.2 47 715 264 74
25% 61 4.6 4.4 1.4 13.5 0.75 27 542 203 42
75% 77 10.7 5.4 2.1 37.2 1.97 65 1020 412 104
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syndrome was based on massive proteinuria and hypoal-
buminemia with or without edema. The study popula-
tion included 14 men and 15 women, with a median age 
of 71  years [interquartile range (IQR), 61–77]. Sixteen 
patients had pathological diagnoses based on kidney 
biopsy: 7 patients with minimal change nephrotic syn-
drome (MCNS), 2 with focal segmental glomeruloscle-
rosis (FSGS), 3 with membranous nephropathy (MN), 2 
with endocapillary proliferative glomerulonephritis (endo-
PGN), and 2 with crescentic glomerulonephritis (crescen-
tic GN). The remaining 13 patients did not undergo kidney 
biopsy due to comorbidities or refusal to provide consent. 
Based on clinical and laboratory findings, these patients 
were suspected of having the following diagnoses: MCNS 
(n = 2), MN (n = 3; 1 with primary MN and 2 with MN 
secondary to malignancy and bucillamine), lupus nephri-
tis (n = 1), essential thrombocytosis (n = 1), diabetes mel-
litus (n = 2), systemic amyloidosis (amyloid light chain 
type) (n = 1), anti-myeloperoxidase (MPO) antineutrophil 
cytoplasmic antibody (ANCA)-associated nephritis (n = 1), 
and no primary disease (n = 1). The median levels of uri-
nary protein, serum total protein (TP), and serum Alb were 
7.0  g/day (IQR, 4.6–10.7), 4.8  g/dL (4.4–5.4), and 1.8  g/
dL (1.4–2.1), respectively. The median blood urea nitrogen 
(BUN) and creatinine (Cr) levels and estimated glomeru-
lar filtration rate (eGFR) were 21.9  mg/dL (13.5–37.2), 
1.2 mg/dL (0.75–1.97), and 47.0 ml/min/1.72 m2 (27–65), 
respectively. The median immunoglobulin G (IgG), IgA, 
and IgM concentrations were 715  mg/dL (542–1020), 
264  mg/dL (203–412), and 74  mg/dL (42–104), respec-
tively (Table 1).
Methods
Serum and urine samples were obtained from all patients 
with nephrotic syndrome before steroid and diuretic 
administration.
Laboratory examinations included TP (g/dL), Alb (g/
dL), BUN (mg/dL), Cr (mg/dL), eGFR (mL/min/1.73 m2), 
Na (mEq/L), K (mEq/L), Cl (mEq/L), Ca (mg/dL), phos-
phate (P) (mg/dL), magnesium (Mg) (mg/dL), lactic acid 
(lactate) (mmol/L), IgG (mg/dL), IgA (mg/dL), IgM (mg/
dL), plasma osmolarity (mOsm/L), arterial blood gas anal-
ysis, plasma renin activity (PRA) (ng/mL/h), and plasma 
aldosterone concentration (PAC) (pg/mL). Urinary exami-
nation was performed to evaluate daily urinary protein (g/
day), urinary protein concentration (mg/dL), urine osmo-
larity (mOsm/L), Na (mEq/L), K (mEq/L), Cl (mEq/L), 
and Cr (mg/dL).
The anion gap (AG) in blood was calculated using 
the formula Na − (Cl + HCO3). The normal range was 
12 ± 2  mEq/L. Corrected AG (cAG) was calculated using 
the formula [AG + 2.5 × (4.4 − measured albumin (g/dL))] 
according to the methods of Nguyen et al. [8] and Rastegar 
[9].
CO2/HCO3 method (traditional Boston model)
Initially, we defined acidemia or alkalemia based on a pH 
of 7.40. Metabolic or respiratory disturbances, and acidosis 
or alkalosis, were determined using the  CO2/HCO3 method. 
In respiratory alkalosis, we diagnosed acute or chronic 
respiratory alkalosis by comparing actual  HCO3 to esti-
mated  HCO3 using Kellum’s compensatory formula [10]. 
Thus, estimated  HCO3 = 0.2 × (actual  PaCO2) + 17 in acute 
respiratory alkalosis and estimated  HCO3 = 0.5 × (actual 
 PaCO2) + 5 in chronic respiratory alkalosis. When there 
was a discrepancy between actual and estimated  HCO3, 
we determined if additional metabolic acidosis or alkalosis 
was present.
Physicochemical method (Stewart model)
We first evaluated several formulas reported by Nguyen 
et al. in 2009 [8], Rastegar in 2009 [9], Kishen et al. in 2014 
[11], and Agrafiotis et al. in 2014 [12]. The Stewart model 
includes the following parameters: carbon dioxide  (PaCO2); 
total concentration of non-volatile weak acids  (ATOT), 
which is the sum of all buffer pairs (mostly weak acids) 
that move toward equilibrium with a dissociated anion  [A−] 
according to its dissociation constant (e.g., albumin with its 
net negative charge under physiological conditions); and 
strong ion difference (SIG). The formulas for  ATOT reported 
by Nguyen et al. [8] and Kishen et al. [11] were incorrect. 
The formula should be  ATOT = Alb (g/dL) × 10 × (0.123 × 
pH − 0.631) + P (mg/dL) × 0.3229 × (0.309 × pH – 0.625) 
according to Rastegar [9], or  ATOT = Alb (g/dL) × 10 × (0.
1204 × pH − 0.625) + P (mg/dL) × 0.3229 × (0.309 × pH − 
0.469) according to Agrafiotis et  al. [12]. Regarding the 
apparent strong ion difference (SIDa), the values for  Ca2+, 
 Mg2+, and lactate are negligible. The formula described 
for effective strong ion difference (SIDe) by Nguyen et al. 
and Kishen et  al. (SIDe =  [HCO3−] + ATOT) was incor-
rect because of errors in their formulas for  ATOT. The units 
for  ATOT, SIDa, SIDe, and SIG should be mEq/L, but not 
mmol/L as described by Kishen et  al.  [HCO3−] in SIDe 
is calculated as 2.46 × 10−8 × PCO2/10(−pH) according to 
Kellum [13] or as 0.0301 × PCO2 × 10(pH−6.1) according to 
Agrafiotis et al. [12]. Ultimately, we decided to use the for-
mulas from Agrafiotis et al. [12]:
ATOT (mEq/L) = [Alb (g/dL)] × 10 × (0.1204 × pH − 0.62
5) + [P (mg/dL)] × 0.3229 × (0.309 × pH − 0.469).
SIDa (mEq/L) = [Na+] + [K+] − [Cl−].
SIDe (mEq/L) = [HCO3−] + ATOT = [0.0301 × PCO2 × 10-
(pH−6.1)] + ATOT.
SIG (mEq/L) = SIDa − SIDe.
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Relationships between albumin and  ATOT 
and between cAG and SIG
We created scatter plots with albumin or cAG on the x-axis 
and  ATOT or SIG on the y-axis. We also derived correlation 
coefficients using Excel (Microsoft Corporation, Redmond, 
WA).
Relationship between eGFR and SIG or (SIG − lactate)
We created scatter plots with eGFR on the x-axis, and SIG 
or (SIG − lactate) on the y-axis. (SIG − lactate) represents 
unknown non-volatile acids other than lactate. We also 
derived correlation coefficients using Excel (Microsoft 
Corporation).
Relationship between IgG and  ATOT, SIDa, SIDe, 
and SIG
We created scatter plots with IgG on the x-axis and  ATOT, 
SIDa, SIDe, or SIG on the y-axis. We also derived correla-
tion coefficients using Excel (Microsoft Corporation).
Results
Serum electrolytes (Table 2)
The median serum concentrations of Na, K, and Cl were 
140 mEq/L (IQR, 137–142), 4.1 (3.7–4.5), and 107 mEq/L 
(104–110), respectively. The concentration of serum K 
was slightly lower than in the control group [4.7  mEq/L 
(4.5–4.8)]. The median actual Ca concentration was signifi-
cantly lower at 7.7 mg/dL (7.1–8.1); however, the median 
Ca concentration corrected for serum albumin was within 
the normal range at 9.8  mg/dL (9.6–10.0). The median P 
and Mg levels were 3.8 (3.3–4.2) and 1.9 mg/dL (1.7–2.0), 
respectively. The median lactate level was 1.3  mmol/L 
(1.0–1.9), which slightly higher than in the control group 
[0.9  mmol/L (0.8–1.0)]. The median IgG, IgA, and IgM 
concentrations were 715 (542–1020), 264 (203–412), and 
74 mg/dL (42–104), respectively.
Traditional model (Boston model)
The median pH was slightly alkalotic at 7.43 (IQR, 
7.42–7.45) (Tables  2, 3); 25 of 29 patients had a pH of 
more than 7.40, while 4 had a pH of less than 7.40. The 
median  PaCO2 was 34.9  Torr (30.8–40.0). Twenty-two 
patients had  PaCO2 levels of less than 40  Torr, while 7 
had levels between 40 and 44.7 Torr. The median A-aDO2 
was 33.9 Torr [28.4–53.6]. Given that the normal limit of 
A-aDO2 is less than 20  Torr, 26 of 29 patients (90%) in 
the high age group had impaired blood gas diffusion. The 
median  PaO2 was 84.2 Torr [70.3–99.8]. These results sug-
gest that hyperventilation occurs in most nephrotic patients. 
Since we routinely exclude pulmonary embolism and infec-
tion using laboratory data and chest computed tomogra-
phy, hypoalbuminemia due to nephrotic syndrome seems 
to induce pulmonary interstitial edema, which in turn 
increases A-aDO2. Hyperventilation then occurs in order 
to maintain  PaO2 levels. Primary respiratory alkalosis is 
essential in patients with nephrotic syndrome. The median 
 HCO3 concentration was 23.7 mEq/L [21.1–26.0]. In cases 
of primary respiratory alkalosis,  HCO3 concentrations 
should be decreased as a result of compensatory mecha-
nisms. Actual  HCO3 concentrations that are higher than 
Table 2  Summary of laboratory data in the nephrotic syndrome and 
control groups
cCa corrected Ca, AG anion gap, cAG corrected anion gap, ATOT non-
volatile weak acids, SIDa apparent strong ion difference, SIGc cor-
rected strong ion gap, Posm plasma osmolarity, Uosm urinary osmo-
larity, U-Na urinary Na, U-K urinary K, U-Cl urinary Cl
Unit Nephrotic syndrome 
group
Control group
Median 25–75% Median 25–75%
Albumin g/dL 1.8 1.4–2.1 4.7 4.5–4.8
Na mEq/L 140 137–142 142 140–145
K mEq/L 4.1 3.7–4.5 4.7 4.5–4.8
Cl mEq/L 107 104–110 105 103–105
Na-Cl mEq/L 33 31–34 37 37–39
Na + K-Cl mEq/L 36.4 35.0–38.0 42.7 41.9–43.3
Ca mg/dL 7.7 7.1–8.1 9.6 9.4–9.8
cCa mg/dL 9.8 9.6–10.0 9.6 9.4–9.8
P mg/dL 3.8 3.3–4.2 3.4 3.0–3.8
Mg mg/dL 1.9 1.7–2.0 2.1 2.0–2.2
Lactate mmol/L 1.3 1.0–1.9 0.9 0.8–1.0
pH 7.43 7.42–7.45 7.40 7.39–7.41
PaCO2 Torr 34.9 30.8–40.0 40.4 39.4–41.1
PaO2 Torr 84.2 70.3–98.8 89.5 87.5–90.1
HCO3 mEq/L 23.7 21.1–26.0 25.1 24.2–25.3
A-aDO2 Torr 33.9 28.4–53.6 10.8 9.6–11.4
AG mEq/L 8.6 7.0–10.8 13.5 13.0–14.5
cAG mEq/L 15.8 13.6–17.4 13.1 12.5–13.5
ATOT mEq/L 7.13 6.00–7.83 14.48 13.73–14.57
SIDa mEq/L 36.4 35.0–38.0 42.7 41.9–43.3
SIDe mEq/L 29.9 27.1–32.9 38.7 38.5–39.3
SIG mEq/L 6.6 4.4–8.2 3.9 3.4–5.1
Posm mOsm/L 287 284–294 nd nd
Uosm mOsm/L 466 296–592 nd nd
U-Na mEq/L 60 37–111 nd nd
U-K mEq/L 31.1 20.2–51.5 nd nd
U-Cl mEq/L 61 31–101 nd nd
Urinary AG mEq/L 38.9 29.0–55.0 nd nd
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expected suggest the coexistence of metabolic alkalosis. In 
nephrotic syndrome, the analysis of acid–base disturbances 
using the Boston method is limited because it requires the 
use of Kellum’s compensatory formula for respiratory alka-
losis [10] or the concept of cAG.
Serum AG (Tables 2, 3)
The median AG was 8.6  mEq/L (IQR, 7.0–10.8), 
which was significantly lower than the normal range of 
12 ± 2 mEq/L. The median cAG, which adjusts for serum 
albumin using the formula cAG = AG + 2.5 × (4.4 − meas-
ured albumin (g/dL)), was 15.8  mEq/L (13.6–17.4). 
Twelve patients had cAG values within the normal 
range of 11.0–15.1  mEq/L, 16 patients had increased 
levels greater than 15.1 mEq/L, and only one patient had 
a slightly decreased level of 10.8 mEq/L (Table 3).
PRA and PAC (Table 4)
PRA values were within the normal range (0.3–2.9  ng/
mL/h) in 19 patients, below normal in 5 patients, and 
above normal in 5 patients. PAC was within the normal 
range (30–160 pg/mL) in 15 patients. Hypoaldosteronism 
was observed in 11 patients, and 3 patients had hyperre-
ninemic hyperaldosteronism. These results demonstrated 
that hypoaldosteronism and normoaldosteronism are the 
predominant conditions in nephrotic syndrome.
Table 3  Blood gas analysis
AG anion gap, cAG corrected anion gap
Patient pH PaCO2 PaO2 HCO3 A-aDO2 AG cAG Lactate
Torr Torr mEq/L Torr mEq/L mEq/L mmol/L
1 7.43 34.0 70.3 22.1 46.8 8.9 16.7 1.3
2 7.48 25.7 110.6 18.9 16.9 11.1 17.4 0.6
3 7.46 34.1 128.3 23.7 79.9 8.3 14.1 1.2
4 7.44 38.7 82.8 26.0 28.4 6.0 12.5 2.1
5 7.45 36.4 106.6 24.8 7.5 5.2 11.5 1.0
6 7.45 35.0 47.3 24.0 68.6 7.0 10.8 1.6
7 7.43 37.4 83.3 24.4 29.6 8.6 13.6 0.9
8 7.44 35.1 98.3 23.5 17.4 7.5 16.0 3.3
9 7.55 27.9 66.6 24.2 58.1 10.8 19.6 2.4
10 7.43 43.2 84.2 28.2 21.4 7.8 15.3 1.8
11 7.34 34.9 85.5 21.2 30.5 11.8 15.8 4.2
12 7.43 41.3 75.7 28.0 32.3 6.0 12.5 0.9
13 7.42 40.8 67.2 25.9 41.4 5.1 13.4 1.5
14 7.56 29.4 92.2 26.1 30.7 9.9 14.9 1.3
15 7.42 42.1 83.6 26.8 23.4 9.2 13.0 1.0
16 7.36 40.0 56.0 22.4 53.6 9.6 15.9 2.6
17 7.47 33.1 80.4 23.7 37.8 7.3 16.1 1.4
18 7.45 36.9 84.8 24.9 28.7 7.1 13.6 0.9
19 7.43 43.9 99.5 28.6 5.2 7.4 13.9 3.8
20 7.42 41.3 59.3 26.1 48.7 9.9 17.4 1.5
21 7.49 28.4 114.4 21.1 100.9 6.9 15.9 1.2
22 7.42 32.0 94.1 20.6 25.5 13.4 19.2 1.7
23 7.43 44.6 62.7 29.4 41.2 5.6 12.9 1.0
24 7.45 30.8 52.4 20.9 68.7 6.1 14.6 1.2
25 7.45 31.9 125.4 21.9 55.1 10.1 16.6 1.2
26 7.48 26.5 77.9 19.3 48.6 13.7 20.2 1.0
27 7.29 31.5 87.9 14.9 32.3 14.1 19.1 0.9
28 7.32 28.7 111.5 14.1 73.0 16.9 22.9 1.9
29 7.40 21.5 98.8 13.1 33.9 16.9 23.2 1.9
Median 7.43 34.9 84.2 23.7 33.9 8.6 15.8 1.3
25% 7.42 30.8 70.3 21.1 28.4 7.0 13.6 1.0
75% 7.45 40.0 98.8 26.0 53.6 10.8 17.4 1.9
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Stewart model (Table 5)
In the control group, the median  ATOT, SIDa, SIDe, 
and SIG values were 14.48 (IQR, 13.73–14.57), 42.7 
(41.9–43.3), 38.7 (38.5–39.3), and 3.9 mEq/L (3.4–5.1), 
respectively. The mean ± SD for  ATOT, SIDa, SIDe, and 
SIG were 14.09 ± 0.90 (normal range: 12.29–15.90), 
42.7 ± 1.4 (normal range: 39.9–45.5), 38.5 ± 1.2 (normal 
range: 36.1–41.0), and 4.2 ± 1.4 (normal range: 1.4–7.0), 
respectively.
PaCO2 (Torr)
The median  PaCO2 level was 34.9 Torr (IQR, 30.8–40.0). 
 PaCO2 was less than 40 Torr in 21 of 29 patients (76%). 
Low  PaCO2 levels, such as those observed here, contrib-
ute to the development of alkalosis (Fig. 1).
ATOT (mEq/L)
ATOT represents the total concentration of non-volatile 
weak acids. It depends on albumin and phosphate levels. 
The median  ATOT was 7.13 (mEq/L) (IQR, 6.00–7.83), 
because hypoalbuminemia secondary to nephrotic syn-
drome directly interferes with  ATOT values. The median 
delta  ATOT, calculated by [14.09 (mean value of control 
group) − ATOT], was 6.96 (6.26–8.09). This lower value 
of  ATOT contributed to metabolic alkalosis (Fig. 1).
Table 4  Plasma and urine 
osmolarity, urinary electrolytes, 
plasma renin activity, 
and plasma aldosterone 
concentration
P-Ald plasma aldosterone concentration, Posm plasma osmolarity, Uosm urinary osmolarity, U-Na urinary 
Na, U-K urinary K, U-Cl urinary Cl
Patient Posm Uosm U-Na U-K U-Cl Urinary AG Renin P-Ald
mOsm/L mOsm/L mEq/L mEq/L mEq/L ng/mL/h pg/mL
1 276 810 20 54.8 46 28.8 19.0 618.0
2 283 722 80 52.0 96 36.0 0.6 10.0
3 284 499 152 19.0 141 30.0 1.1 39.1
4 287 528 117 34.6 90 61.6 0.1 10.0
5 282 592 127 46.2 141 32.2 0.2 40.1
6 281 290 53 22.0 49 26.0 13.0 191.0
7 293 602 155 28.4 133 50.4 0.4 70.1
8 290 818 42 68.4 108 2.4 16.0 309.0
9 298 749 81 39.2 81 39.2 18.0 77.4
10 285 417 39 20.1 31 28.1 1.5 67.8
11 306 432 113 17.0 101 29.0 0.8 101.0
12 285 244 114 100.0 159 55.0 0.6 10.0
13 294 813 36 61.9 39 58.9 2.6 45.0
14 286 466 105 32.3 87 50.3 0.7 27.9
15 294 475 85 31.1 72 44.1 1.6 50.4
16 282 328 138 26.9 126 38.9 0.5 19.2
17 293 560 56 30.1 21 65.1 0.4 10.0
18 286 484 37 51.5 22 66.5 0.9 33.6
19 301 392 111 32.3 86 57.3 0.8 10.0
20 332 796 18 72.3 12 78.3 0.7 16.4
21 281 453 26 42.9 25 43.9 0.5 32.1
22 287 474 62 24.5 46 40.5 13.0 85.6
23 291 296 109 14.7 110 13.7 0.4 10.0
24 267 264 33 27.4 31 29.4 0.4 26.7
25 297 275 33 16.6 16 33.6 2.9 20.6
26 285 248 48 20.2 40 28.2 0.2 53.1
27 310 431 35 57.1 25 67.1 1.2 50.8
28 302 274 41 19.1 24 36.1 0.3 59.1
29 286 196 60 15.8 61 14.8 0.1 72.4
Median 287 466 60 31.1 61 38.9 0.7 40.1
25% 284 296 37 20.2 31 29.0 0.4 19.2
75% 294 592 111 51.5 101 55.0 1.6 70.1
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SIDa (mEq/L)
SIDa reflects the likelihood of alkalosis. The median SIDa 
value, calculated by [Na + K − Cl], was 36.4 (mEq/L) (IQR, 
35.0–38.0), which was lower than the mean value in the 
control group (42.7 mEq/L). The median delta SIDa, cal-
culated by [42.7 (mean value of control group) − SIDa], 
was 6.3 (mEq/L) (4.7–7.7). Lower SIDa among nephrotic 
patients suggests a power to metabolic acidosis (Fig. 1). In 
individual patients, delta  ATOT (alkalosis) greater than delta 
SIDa (acidosis) results in metabolic alkalosis. Inversely, 
when delta SIDa is greater than delta  ATOT, the patient has 
metabolic acidosis with a normal anion gap.
SIDe (mEq/L)
The median SIDe was 29.9  mEq/L (IQR, 27.1–32.9), 
which was lower than the mean value in the control group 
(38.5 mEq/L).
SIG (mEq/L)
SIG reflects the accumulation of various non-volatile acids, 
including lactate or uremic substances. Increased AG sug-
gests metabolic acidosis with an increased anion gap. The 
median SIG was 6.6  mEq/L (IQR, 4.4–8.2), which was 
higher than 3.9 mEq/L (3.4–5.1) in the control group. The 
Table 5  Data from the Stewart model
Control group mean values:  ATOT, 14.09; SIDa, 42.7; SIG, 4.2; lactate, 0.9
Patient pH PaCO2 ATOT Delta  ATOT 
(to alkalosis)




SIDe SIG Increased 
AG acidosis
Lactate SIG-lactate
Torr 14.09 42.7 38.9 1.4–7.0 mmol/L mEq/L
1 7.43 34.00 6.16 7.93 34.8 7.9 Neutral 28.1 6.7 1.3 5.4
2 7.48 25.70 7.69 6.40 34.1 8.6 Acidosis 26.4 7.7 AG+ 0.6 7.0
3 7.46 34.10 7.69 6.40 35.8 6.9 Acidosis 31.2 4.6 1.2 3.5
4 7.44 38.70 7.13 6.96 36.5 6.2 Alkalosis 32.8 3.7 2.1 1.6
5 7.45 36.40 7.47 6.62 34.4 8.3 Acidosis 31.9 2.5 1.0 1.5
6 7.45 35.00 9.49 4.60 35.2 7.5 Acidosis 33.2 2.0 1.6 0.4
7 7.43 37.40 8.60 5.49 37.1 5.6 Acidosis 32.8 4.3 0.9 3.5
8 7.44 35.10 5.02 9.07 35.1 7.6 Alkalosis 28.2 6.9 3.3 3.6
9 7.55 27.90 4.91 9.18 38.0 4.7 Alkalosis 28.7 9.3 AG+ 2.4 6.8
10 7.43 43.20 5.02 9.07 40.6 2.1 Alkalosis 33.0 7.6 AG+ 1.8 5.8
11 7.34 34.90 8.93 5.16 37.3 5.4 Acidosis 27.1 10.2 AG+ 4.2 6.0
12 7.43 41.30 6.67 7.42 37.9 4.8 Alkalosis 33.1 4.8 0.9 3.9
13 7.42 40.80 5.25 8.84 35.3 7.4 Alkalosis 30.9 4.4 1.5 2.9
14 7.56 29.40 8.91 5.18 39.7 3.0 Alkalosis 34.7 5.0 1.3 3.7
15 7.42 42.10 10.44 3.65 40.3 2.4 Alkalosis 37.0 3.3 1.0 2.3
16 7.36 40.00 7.83 6.26 36.5 6.2 Neutral 29.9 6.6 2.6 4.0
17 7.47 33.10 3.89 10.20 34.5 8.2 Alkalosis 27.2 7.3 AG+ 1.4 6.0
18 7.45 36.90 6.84 7.25 36.4 6.3 Alkalosis 31.5 4.9 0.9 4.0
19 7.43 43.90 7.04 7.05 39.5 3.2 alkalosis 35.4 4.1 3.8 0.4
20 7.42 41.30 7.05 7.04 41.1 1.6 Alkalosis 32.9 8.2 AG+ 1.5 6.7
21 7.49 28.40 4.24 9.85 31.7 11.0 Acidosis 25.3 6.4 1.2 5.2
22 7.42 32.00 7.77 6.32 38.9 3.8 Alkalosis 28.1 10.8 AG+ 1.7 9.1
23 7.43 44.60 6.00 8.09 38.5 4.2 Alkalosis 35.0 3.5 1.0 2.5
24 7.45 30.80 5.20 8.89 30.7 12.0 Acidosis 25.8 4.9 1.2 3.6
25 7.45 31.90 7.27 6.82 36.5 6.2 Alkalosis 29.0 7.5 AG+ 1.2 6.4
26 7.48 26.50 6.69 7.40 36.0 6.7 Alkalosis 25.9 10.1 AG+ 1.0 9.1
27 7.29 31.50 8.89 5.20 35.0 7.7 Acidosis 23.6 11.4 AG+ 0.9 10.4
28 7.32 28.70 8.53 5.56 36.4 6.3 Acidosis 22.8 13.6 AG+ 1.9 11.7
29 7.40 21.50 7.64 6.45 33.9 8.8 Acidosis 20.6 13.3 AG+ 1.9 11.4
Median 7.43 34.90 7.13 6.96 36.4 6.3 29.9 6.6 1.3
25% 7.42 30.80 6.00 6.26 35.0 4.7 27.1 4.4 1.0
75% 7.45 40.00 7.83 8.09 38.0 7.7 32.9 8.2 1.9
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mean ± SD in the control group was 4.2 ± 1.4 mEq/L (nor-
mal range: 1.4–7.0).
Lactate (mmol/L = mEq/L) and SIG (mEq/L)
The median lactate was 1.3 mmol/L (IQR, 1.0–1.9), higher 
than 0.9 mmol/L (0.8–1.0) in the control group. The mean 
was 0.9  mmol/L (normal range: 0.8–1.0). Lactate levels 
greater than 1.0 mmol/L were observed in 20 of 29 patients 
(69%), and 12 out of 29 patients had metabolic acidosis 
with an increased anion gap. (SIG − lactate) represents the 
accumulation of non-volatile acids except for lactate. Seven 
of 12 patients had mainly lactate accumulation. Three had 
accumulation of lactate and non-volatile acids such as ure-
mic toxins. Two of 12 patients had accumulation of non-
volatile acids except for lactate.
Relationship between serum albumin and  ATOT
There was a strong significant relationship between 
serum albumin and  ATOT:  ATOT = 2.6425 × Alb + 2.3323 
(R2 = 0.91851) (Fig. 2a). We can easily calculate and esti-
mate  ATOT using serum albumin alone. When the serum 
albumin level is 4.4  g/dL,  ATOT will be 14.0, a normal 
value (14.09). If the albumin level is 1.5 g/dL,  ATOT will be 
6.30. In addition, delta  ATOT, which represents the power 
to metabolic alkalosis, is calculated using the formula 
11.77 − 2.64 × Alb (g/dL) (Fig. 1).
Relationship between cAG and SIG
We estimated SIG using the formula 
SIG = 0.9463 × cAG − 8.1956 (R2 = 0.91057) (Fig.  2b). 
After calculating delta cAG [cAG − 12], the formula 
can be rewritten as SIG = 0.9463 × delta cAG + 3.1605 
(R² = 0.91057).
Relationship between eGFR and SIG or (SIG − lactate)
The relationship between eGFR and SIG is as follows: 
SIG = − 4E−10(eGFR)6 + 1E−07(eGFR)5 − 1E−05(e
GFR)4 + 0.0003(eGFR)3 + 0.018(eGFR)2 − 1.0314(eG
FR) + 19.046 (R2 = 0.5943). The relationship between 
eGFR and (SIG − lactate) is as follows: (SIG − lactate) = 
 − 5E−10(eGFR)6  + 2E−07(eGFR)5 − 2E−05(eGFR)4 
+ 0.0008(eGFR)3 − 4E−05(eGFR)2 − 0.7119(eGFR) + 
15.952 (R2 = 0.6589) (Fig.  2c, d). Six of 9 patients with 
eGFR less than 29 mL/min/1.72 m2 had metabolic acido-
sis with an increased anion gap. Five out of 6 patients had 
accumulation of lactate and unknown non-volatile acids 
(i.e., uremic toxins). One patient had increased lactate lev-
els alone. On the other hand, patients with eGFR greater 
than 30 mL/min/1.72 m2 who had metabolic acidosis with 
an increased anion gap had increased lactate levels.
Relationship between IgG and  ATOT, SIDa, SIDe, 
and SIG
Levels of IgG, a positively charged protein, might influ-
ence acid–base balance. The relationship between IgG 
Fig. 1  Determination of pH in 
the Stewart model. In the Stew-
art model,  PaCO2,  ATOT, and 
SIGc have powers toward aci-
dosis. On the other hand, SIDa 
has a power toward alkalosis. In 
healthy individuals, pH should 
be 7.40. In nephrotic syndrome, 
patients are alkalotic due to 
decreased levels of  PaCO2, 
decreased  ATOT due to hypoal-
buminemia, and decreased SIDa 
resulting from hyperchloremia 
due to hyporeninemic hypoaldo-
steronism
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and  ATOT, SIDa, SIDe, and SIG can be expressed as 
 ATOT = −0.0002 × (IgG) + 7.2633 (R² = 0.0073), SID
a = − 0.0029 × (IgG) + 39.076 (R² = 0.4337), SID
e = − 0.0046 × (IgG) + 33.834 (R² = 0.4105), and 
SIG = 0.0017 × (IgG) + 5.242 (R² = 0.0943), respectively. In 
other words, IgG levels have a negligible influence in the 
Stewart model.
Discussion
This study revealed 4 specific findings about acid–base 
disturbances in nephrotic syndrome. First, primary respira-
tory alkalosis occurs due to respiratory dysfunction, with 
elevated A-aDO2 caused by pulmonary interstitial edema 
due to hypoalbuminemia. Second, the comparison between 
delta  ATOT and delta SID helps to determine whether 
metabolic alkalosis or metabolic acidosis with a normal 
anion gap is present. Third, we can estimate  ATOT using 
serum albumin, SIDa as Na + K − Cl, and SIG using cAG. 
Fourth, 90% of patients had hyporeninemic or normore-
ninemic hypoaldosteronism, not hyperreninemic hyperal-
dosteronism. The above findings suggest that hyperchlo-
remic metabolic acidosis in nephrotic syndrome is due to 
hyporeninemic hypoaldosteronism, with a shift of K into 
the intracellular space due to alkalemia.
The Boston model is easy for beginners to understand 
and use to analyze acid–base disturbances. However, with-
out the use of compensatory formulas described by Kel-
lum [10], this model is limited in the setting of complex 
conditions such as respiratory abnormalities and 2 or more 
concurrent metabolic abnormalities. It is very hard not only 
for beginners, but also for nephrologists to understand and 
calculate the effects of compensatory mechanisms. On the 
Fig. 2  Relationship between albumin,  ATOT, eGFR, and SIG. a Rela-
tionship between albumin and  ATOT:  ATOT = 2.6425 × Alb + 2.3323 
(R2 = 0.91851). Delta  ATOT is calculated as 11.77 − 2.64 × Alb 
(g/dL). This number indicates the power to alkalosis. b Relationship 
between cAG and SIG: SIG = 0.9463 × cAG − 8.1956  (R2 = 0.91057). 
c Relationship between eGFR and SIG: SIG = − 4E-10(eGFR)6 + 
1E−07(eGFR)5 − 1E−05(eGFR)4 + 0.0003(eGFR)3 + 0.018(eGFR
)2 − 1.0314(eGFR) + 19.046  (R2 = 0.5943). d Relationship between 
eGFR and SIG − lactate: (SIG-lactate) = − 5E−10 (eGFR)6 + 2E-07 
(eGFR)5 − 2E−05 (eGFR)4 + 0.0008 (eGFR)3 − 4E−05 (eGFR)2 − 
0.7119 (eGFR) + 15.952 (R2 = 0.6589) (c, d). Six out of 9 patients 
with eGFR less than 29 mL/min had metabolic acidosis with an 
increased anion gap. Five out of 6 patients had accumulation of lac-
tate and unknown non-volatile acids (i.e., uremic toxins). One patient 
had increased levels of lactate alone. On the other hand, increased 
lactate levels were observed in patients with eGFR greater than 
30 mL/min, who have metabolic acidosis and an increased anion gap
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other hand, the Stewart model is theoretically superior to 
the Boston model in complex situations because it is based 
on physicochemical data. Changes after treatment such as 
supplementation of solution or albumin can be evaluated 
and be estimated using the Stewart model. The present 
study revealed that the formula from Agrafiotis et al. [12] 
is the most reliable; several manuscripts including those 
by Nguyen et al. [8], Restegar [9], and Kishen et al. [11], 
contained incorrect formulas. A lack of consensus on for-
mulas for the Stewart model limits its use. Masevicius and 
Dubin [14] claimed that the Stewart approach is cumber-
some, requires more determinations and calculations, and 
is more time-consuming and expensive. They only need to 
continue with the proper use of the Boston model. How-
ever, this study suggested that a combination of the Bos-
ton and Stewart models would be important to consider in 
complicated cases such as mixed metabolic disorders and 
hypoalbuminemia.
In the Steward model, the first step in the approach to 
analyzing acid–base disturbances in nephrotic syndrome 
is calculating delta  ATOT and delta SIDa. The second step 
is comparing delta  ATOT and delta SIDa values. When 
delta  ATOT (14.1 − measured  ATOT) is greater than delta 
SIDa (49.2 − measured SIDa), we can predict the pres-
ence of metabolic alkalosis. Inversely, when delta  ATOT is 
smaller than delta SIDa, metabolic acidosis with a normal 
anion gap is likely to be present. Thus, we can easily dis-
tinguish between metabolic alkalosis and metabolic aci-
dosis using delta  ATOT and delta SIDa values. This study 
also demonstrated a strong relationship between  ATOT and 
serum albumin and between SIG and cAG. We can esti-
mate  ATOT and delta  ATOT using the following formulas: 
 ATOT = 2.6425 × Alb + 2.3323 (R2 = 0.91851) and delta 
 ATOT = 11.77 − 2.64 × Alb (g/dL) (power to alkalosis). 
Since SIDa is calculated as (Na + K − Cl), the formula for 
delta SIDa is (49.2 − measured SIDa), which indicates the 
power to acidosis. In addition, we can identify another met-
abolic acidosis with an increased anion gap using the for-
mula SIG = 0.9463 × cAG − 8.1956 (R2 = 0.91057). (more 
than 7.0). The reliability of the estimated formula is 89.7% 
(26/29) in metabolic alkalosis or acidosis with a normal 
anion gap and 86.2% (25/29) in metabolic acidosis with an 
increased anion gap (data not shown). Our formulas will 
help [who?] understand mixed acid–base disturbances in 
nephrotic syndrome and renal failure.
The present study revealed that patients with eGFR less 
than 29 mL/min/1.72 m2 mainly have accumulation of lac-
tate and uremic toxins. On the other hand, patients with 
eGFR greater than 30 mL/min/1.72 m2 have metabolic aci-
dosis with an increased anion gap as a result of increased 
lactate levels alone. Systemic edema due to nephrotic syn-
drome from MCNS or FSGS may influence the production 
of lactate.
Regarding the mechanism of edema in nephrotic syn-
drome, the underfill and overfill hypotheses have been 
proposed [15]. According to the underfill hypothesis, 
the renin–angiotensin–aldosterone system is activated 
by decreased intravascular blood volume, which in turn 
induces sodium retention and causes edema. However, 
the present study demonstrated that only 10% of patients 
have hyperreninemic hyperaldosteronism, while 90% had 
hypoaldosteronism or normoaldosteronism. These data 
support the overfill hypothesis [16, 17]. Fluid manage-
ment should involve administration of albumin and loop 
diuretics. Anti-aldosterone drugs such as spironolactone 
and eplerenone should be avoided. Recently, acetazola-
mide and hydrochlorothiazide followed by furosemide 
have been reported to be more effective for the treatment 
of refractory nephrotic edema [18]. However, the influence 
of these treatments on acid–base disturbances in nephrotic 
syndrome should be further studied because acetazolamide 
induces metabolic acidosis by increasing urinary excretion 
of  Na+ and  HCO3−.
Conclusion
We showed that patients with nephrotic syndrome have pri-
mary respiratory alkalosis, decreased  ATOT due to hypoal-
buminemia (power to metabolic alkalosis), decreased SIDa 
(power to metabolic acidosis), and increased SIG, suggest-
ing that they accumulate non-volatile acids such as lac-
tate, uremic toxins, or other acids. Using both the Stewart 
and Boston methods facilitates the analysis of complex 
acid–base disturbances in primary and secondary nephrotic 
syndrome.
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